Conference Perspectives

View all perspectives
      BARI reduces nociplastic pain, small cohort RA n=13
      -wk 12 ACR FM score 14 vs 10.5 p=0.03
      -fMRI data: reduction connect

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      BARI reduces nociplastic pain, small cohort RA n=13 -wk 12 ACR FM score 14 vs 10.5 p=0.03 -fMRI data: reduction connectivity between DMN and posterior insula & between IPL & anterior/middle insular regions Directs mechanims yet to be investigated @RheumNow POS0310 #EULAR2024 https://t.co/jGgvS5qqV6
      Is RA always preceded by clinically suspect arthralgia? Cohort 650+ pts CSA = 83 pts no CSA = 616 pts
      Pts w/ no CSA:

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      Is RA always preceded by clinically suspect arthralgia? Cohort 650+ pts CSA = 83 pts no CSA = 616 pts Pts w/ no CSA: -older -more frequent acute onset of symptoms -higher SJC -increased CRP -less ACPA+ No sure how accounted for memory bias #EULAR2024 @RheumNow POS1030 https://t.co/dJeN41ax5P
      9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylate

      Peter Nash drpnash

      3 months 2 weeks ago
      9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
      EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-

      Peter Nash drpnash

      3 months 2 weeks ago
      EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024
      EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (

      Peter Nash drpnash

      3 months 2 weeks ago
      EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024
      FAPI PET/CT entheseal & synovial fibroblast activation predicts PsA in high risk PsO better than MUS @RheumNow #EULA

      Peter Nash drpnash

      3 months 2 weeks ago
      FAPI PET/CT entheseal & synovial fibroblast activation predicts PsA in high risk PsO better than MUS @RheumNow #EULAR2024 https://t.co/uqmEvMg9WN
      more evidence in PsA - switch MOA rather than cycle within class failed first TNF @RheumNow #EULAR2024 https://t.co/hf2U

      Peter Nash drpnash

      3 months 2 weeks ago
      more evidence in PsA - switch MOA rather than cycle within class failed first TNF @RheumNow #EULAR2024 https://t.co/hf2UB5MXEy
      opposing point of view especially in males at 3 years !@RheumNow #EULAR2024 https://t.co/CXxIScQbFD

      Peter Nash drpnash

      3 months 2 weeks ago
      opposing point of view especially in males at 3 years !@RheumNow #EULAR2024 https://t.co/CXxIScQbFD
      computer screen safety
      Impact of regulatory warning on JAK inhibitors
      3 months 2 weeks ago
      The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using JAKi in patients with certain risk factors, e.g., ≥65 years, at increased risk of MACE, current smoker or past smoker and at increased risk of cancer,
      #wasup in #GCA?

      #upadacitinib +RCT in #temporal #arteritis LBA0001

      Residual #inflammation in 1/3 of pts at 6 mo #Rx w

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      #wasup in #GCA? #upadacitinib +RCT in #temporal #arteritis LBA0001 Residual #inflammation in 1/3 of pts at 6 mo #Rx w #TCZ on repeat TA Bx OP0621 #PMR cases #Leflunomide beats #MTX for #pred sparing ⬇️relapses But MTX dose was low POS0280 #EULAR2024 @RheumNow @eular_org
      New #JAKi #disease #results

      #Baricitinib in #alopecia #areata esp 4mg/d

      #Upadacitinib in Crohn’s

      #Upa in #polyartic

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      New #JAKi #disease #results #Baricitinib in #alopecia #areata esp 4mg/d #Upadacitinib in Crohn’s #Upa in #polyarticular #JIA & kid #PsA +RCT of UPA in #GCA Awaiting results of #SLE With #deucravicitinib & UPA #RCTs #EULAR2024 @eular_org @RheumNow
      #Behcet’s #syndrome is increasing in the UK

      ? ⬆️ Detection

      ? Changing population demographics

      ? Other reasons

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      #Behcet’s #syndrome is increasing in the UK ? ⬆️ Detection ? Changing population demographics ? Other reasons Poster discussion POS0258 #EULAR2024 @RheumNow @eular_org @Pr1yankaC https://t.co/SEzmJnFMhM
      When would I use
      #Aclasta vs #Prolia since #denosumab has LESS #fractures

      ▶️younger women with #osteoporosis requ

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      When would I use #Aclasta vs #Prolia since #denosumab has LESS #fractures ▶️younger women with #osteoporosis requiring Rx due to long safety ▶️less wearing off when stopping it ▶️noncompliant Pts as prolia reverses effect when dose is missed @RheumNow #EULAR2024 @eular_org https://t.co/0RTGx0sCTd
      Agree!
      Liz Volkmann said it straight

      Unsustainable RCTs in ILD trials in #scleroderma

      Why
      Can’t recruit
      ~same pool

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      Agree! Liz Volkmann said it straight Unsustainable RCTs in ILD trials in #scleroderma Why Can’t recruit ~same pool of early #dcSSc design RCT UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr 🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM
      I think if we’re worried about JAK inhibitor safety, we need to be doing it right.

      I wrote this for @RheumNow for #EU

      David Liew drdavidliew

      3 months 2 weeks ago
      I think if we’re worried about JAK inhibitor safety, we need to be doing it right. I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read: https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg

      Podcasts

      • Which One Is The Loneliest Number (9.27.2024)
      • I Cant Treat Ugly (9.20.2024)
      • Systemic Sclerosis Insights (9.13.2024)

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.